Nabil Hafez, CEO of Genomate Health, will attend the Oncology Venture, Innovation & Partnering Summit on October 19–20 in Cambridge, Massachusetts, to meet investors and potential partners advancing cancer therapeutics and diagnostics.

‍

The summit brings together oncology executives, entrepreneurs, pharmaceutical leaders, and investors for discussions on funding, business development, and emerging approaches to cancer innovation. This year’s agenda includes the role of artificial intelligence in oncology drug development and healthcare, a topic closely connected to Genomate Health’s work. Our computational reasoning technology is designed to connect the molecular characteristics of a tumor with evidence about how cancer drugs work. In drug development, this means exploring which patient populations may benefit from a therapy and where additional development opportunities may exist.

These opportunities span new therapies, new indications for existing drugs, and the reassessment of assets that have fallen short in earlier studies. Across them, our focus is the same: using a deeper understanding of tumor biology to inform what to pursue next.

Nabil will be available to discuss investment and strategic partnerships supporting this work.

‍

Joining the Oncology VIP Summit? Get in touch  to arrange a meeting with Nabil ↗